Immunome Reports Widening Q2 Loss, Advances Pipeline with Varegacestat NDA Acceptance and New Phase 1 Trials

summarizeSummary

Immunome Inc. reported a wider Q2 net loss but achieved a major milestone with the FDA's acceptance of its varegacestat NDA, alongside advancing two other clinical programs.

check_boxKey Events · Product Development and Regulatory · IMNM

• Q2 Net Loss Widens Significantly

  Immunome reported a net loss of $73.1 million for Q2 2026, a substantial increase from $53.8 million in Q1 2026 and $43.4 million in Q2 2025, reflecting increased R&D and administrative expenses.

• Cash Position Decreases

  Cash and cash equivalents, combined with marketable securities, totaled approximately $530 million as of June 30, 2026, down from $582.7 million in Q1 2026.

• Varegacestat NDA Accepted by FDA

  The FDA accepted the New Drug Application (NDA) for varegacestat for progressing desmoid tumors, setting a Prescription Drug User Fee Act (PDUFA) target action date of April 28, 2027. This follows positive Phase 3 trial results.

• Pipeline Expansion with New Phase 1 Trials

  The company initiated Phase 1 clinical trials for IM-1617 (a potential first-in-class ADC for solid tumors) in June 2026 and IM-3050 (a FAP-targeted radioligand therapy for solid tumors) in July 2026.

auto_awesomeAnalysis · IMNM · Life Sciences

Immunome Inc.'s second-quarter report highlights significant progress in its clinical pipeline, most notably the FDA's acceptance of the New Drug Application (NDA) for varegacestat with a PDUFA target action date of April 28, 2027. This is a critical step towards potential commercialization of its lead candidate. The company also initiated two new Phase 1 trials for IM-1617 and IM-3050, demonstrating active pipeline expansion. However, these advancements come with a widening net loss of $73.1 million for the quarter and increased cash burn, reducing cash and marketable securities to approximately $530 million. The company projects a cash runway of at least 12 months.